Hillevax Inc's ROI from its second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Hillevax Inc's ROI in the second quarter of 2025?
Hillevax Inc recorded a cumulative net loss of $-71 million during 12 months ending in the second quarter of 2025, resulting in a negative return on investment (ROI) of -39.28%.

Within the Healthcare sector 464 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2025 from 0 to 3753.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Investment Change TTM	-38.61 %	-35.8 %	-25.87 %	-13.64 %	1.02 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	169	172	176	207	228
Return On Investment (TTM)	-39.28 %	-54.4 %	-65.51 %	-57.9 %	-53 %
HLVX's Overall Ranking	# 3753	# 0	# 3948	# 3731	# 3662
Seq. Investment Change TTM	-7.53 %	-12.92 %	-13.38 %	-11.97 %	-3.31 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-71	-106	-147	-150	-156

HLVX Company Profile >> Back to HLVX Roi Comparisons >> See Annual HLVX Return On Investment

Return On Investment HLVX's Ranking
Within:	No.
Industry	# 61
Sector	# 465
Overall	# 3753

Return On Investment Statistics
High	Average	Low
-31.79 %	-49.67 %	-82.15 %
(Jun 30 2023)		(Dec 31 2022)

News about Hillevax Inc Return on Investment ROI

Amid Setbacks, HilleVax Inc. Faces a Crossroads Navigating Workforce Cuts and Stagnant Shares in Biopharmas High-Stakes Arena

August 5, 2024

HilleVax Inc Faces Tumultuous Waters: 2024 Struggles Amid Norovirus Vaccine Setbacks and Workforce Reductions In an unforgiving landscape fueled by rigorous competition and increasing economic pressures, HilleVax Inc. (NASDAQ: HLVX), a Boston-based biopharmaceutical company, is currently experiencing significant challenges in the market, trailing with a performance 12.32% below that of the broader industry this year. Having recorded a staggering cumulative net loss totaling $108 million in the twelve months ending in the third quarter of 2023, HilleVax has seen its return on investment (ROI) plummet to -35.87%. As the company grapples with these financial headwinds, a recent series of staffing reductions and operational scaling raises questions about its future trajectory.The current discontent surrounding HilleVax shares can largely be traced back to a disappointing outcome from its Phase IIb clinical trial for its lead norovirus vaccine, which catalyzed a wave of negative market sentiment. On August 1, 2024, just after the announcement of the trial failure, HilleVax revealed plans to cut approximately 40% of its workforce amounting to the layoff of 41 employees as part of its efforts to streamline operations. This decision directly points to the profound impact of clinical setbacks on personnel decisions within biotechnology sectors. Moreover, the clinical trial results not only led to immediate workforce adjustments but also prompted deeper investigations by law firms on behalf of investors regarding potential claims against the company.

HilleVax Takes Measures to Stem Financial Losses, Announces Workforce Reduction

July 31, 2024

BOSTON, July 31, 2024 - HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company specializing in developing and commercializing innovative vaccines, has revealed plans to downsize its workforce in a bid to reduce operational expenses. The company intends to lay off approximately 41 employees, which amounts to around 40% of its workforce, as a strategic move to preserve cash while continuing the development of its HIL-214 and HIL-216 norovirus vaccine candidates, as well as drive business development activities in support of these vaccines.
This decision comes at a time when HilleVax has encountered significant financial challenges. Over the past 30 days, their stock, HLVX, has experienced a substantial decline of -87%. Moreover, data shows that Hillevax Inc recorded a cumulative net loss of $-108 million during the twelve-month period ending in the third quarter of 2023, leading to a negative return on investment (ROI) of -35.87%. This places the company among the lower performers in terms of ROI within the healthcare sector, with 470 other companies boasting higher returns on investment.

Financial Statements
Hillevax Inc's II. Quarter Investments	$ 169 Millions	HLVX's Balance sheet
Hillevax Inc's II. Quarter Income	$ -5 Millions	Quarterly HLVX's Income Statement
HLVX's Income by Division		See HLVX's Income by Division

HLVX Annual Return On Investment	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022
Total Investments in Millions	176	315	304	0	0
Y / Y Investment Growth	-44.08 %	3.62 %	-	-	-
Net Income in Millions	-147	-124	-160	0	0
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-83.56 %	-39.21 %	-52.54 %	-	-

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
HLVX's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for HLVX's Competitors
Subscribers only: Roi for Hillevax Inc's Suppliers
Subscribers only: Return On Investment for HLVX's Customers

Other Ratios
HLVX's Roa	HLVX's Inventory Turnover Ratio	HLVX's Growth Rates	HLVX's Dividend Statistics
	HLVX's Profitability Ratios	HLVX's Asset Turnover Ratio	HLVX's Dividend Growth
HLVX's Roe	HLVX's Valuation Ratios	HLVX's Financial Strength Ratios	HLVX's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2025, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:41:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.